grant
Characterizing the theranostic potential of DLL3-targeting agents in high-grade neuroendocrine carcinomas of the lung and prostate
Organization SLOAN-KETTERING INST CAN RESEARCHLocation NEW YORK, UNITED STATESPosted 2 Jul 2024Deadline 30 Jun 2028
NIHUS FederalResearch GrantFY2025AffectAfter CareAfter-TreatmentAftercareAmerican maleAmerican manAmerican menAntibodiesAntigensAntioncogene Protein p53Armed Forces PersonnelBiologicalBiopsyBloodBlood Reticuloendothelial SystemBody TissuesCTCAECancer CauseCancer EtiologyCancer PatientCancersCell surfaceCellular Tumor Antigen P53Cessation of lifeClinicalClinical Treatment MoabCommon Terminology Criteria for Adverse EventsCommon Toxicity CriteriaDTPADataDeathDetarexDevelopmentDiagnosisDiagnosticDiethylenetriamine Pentaacetic AcidDiseaseDisorderDoseDrugsExhibitsGene ExpressionGeneticGenomicsGoalsGolgiGolgi ApparatusGolgi ComplexImageIntelligenceIntratumoral heterogeneityLesionLigandsLung CarcinomaLung Neuroendocrine NeoplasmMalignant NeoplasmsMalignant TumorMalignant Tumor of the LungMalignant neoplasm of lungMalignant neoplasm of prostateMalignant prostatic tumorMedicationMetastasisMetastasizeMetastatic LesionMetastatic MassMetastatic NeoplasmMetastatic TumorMilitaryMilitary PersonnelModelingModificationMolecularMolecular FingerprintingMolecular ProfilingMonitorMonoclonal AntibodiesNeoplasm MetastasisNeuroendocrineNeuroendocrine CarcinomaNeuroendocrine NeoplasmNeuroendocrine Prostate CancerNeuroendocrine SystemNeuroendocrine TumorsNeurosecretory SystemsNormal TissueNormal tissue morphologyOat cell carcinomaOncoprotein p53Outcome MeasureP53PETPET ScanPET imagingPET/CTPET/CT scanPETSCANPETTPatientsPentaindPentetic AcidPenthanilPeptide ReceptorPharmaceutical PreparationsPhase I StudyPhenotypePhosphoprotein P53Phosphoprotein pp53PositionPositioning AttributePositron Emission Tomography Medical ImagingPositron Emission Tomography ScanPositron-Emission TomographyPredispositionProstate CAProstate CancerProstate NeoplasmsProstate TumorProstate carcinomaProstate malignancyProstatic NeoplasiaProstatic NeoplasmsProstatic carcinomaProtein TP53ProteinsPulmonary CancerPulmonary Neuroendocrine NeoplasmPulmonary Neuroendocrine TumorPulmonary malignant NeoplasmRB1RB1 geneRad.-PETRadarRadiationRadiation DoseRadiation Dose UnitRadiation SensitivityRadiation ToleranceRadiation therapyRadioactiveRadioimmunoconjugateRadiolabeledRadiolabeled AntibodiesRadionuclide therapyRadiopharmaceutical CompoundRadiopharmaceuticalsRadiosensitivityRadiotheranosticsRadiotherapeuticsRadiotherapyReportingSafetySecondary NeoplasmSecondary TumorSerious Adverse EventSevere Adverse EventSiteSmall Cell Lung CancerSolid NeoplasmSolid TumorSurvey InstrumentSurveysSusceptibilityTM-MKRTP53TP53 geneTRP53Theranostic RadiopharmaceuticalsTherapeuticTissuesToxic effectToxicitiesTranscriptTranslationsTreatment EfficacyTumor MarkersTumor Protein p53Tumor Protein p53 GeneU.S. MalesUS MenUS maleValidationVisceraladvanced prostate cancerbiologicbonebone imagingbone scanningcancer metastasiscancer typecarcinoma prostatic cancerdevelopmentaldosimetrydrug/agentexperiencegenomic toolsheterogeneity in tumorsimagingimmunogenintervention efficacyintra-tumoral heterogeneityintratumor heterogeneitylung cancerlung neuroendocrine tumorlung oat cell carcinomalung small cell neuroendocrine carcinomamAbsmalemales in Americamales in the U.S.males in the USmales in the USAmales in the United Statesmalignancymeasurable outcomemen in Americamen in the U.S.men in the USmen in the USAmen in the United Statesmilitary populationmolecular profilemolecular signaturemonoclonal Absmortalitymutational statusneoplasm/cancerneuroendocrine cancerneuroendocrine malignancynon-invasive diagnosisnon-invasive diagnosticnon-invasive monitornoninvasive diagnosisnoninvasive diagnosticnoninvasive monitornoveloat cell canceroutcome measurementoverexpressoverexpressionp53 Antigenp53 Genesp53 Tumor Suppressorphase 1 studypositron emission computed tomographypositron emission tomographic (PET) imagingpositron emission tomographic imagingpositron emitting tomographypost treatmentprostate cancer modelprostate tumor modelprotein p53radiation treatmentradio-sensitivityradioactive drugsradiolabelingradiologically labeledradionuclide theranosticsradionuclide-based theranosticsradiopharmaceutical-based theranosticsradiosensitiveradiotherapeutic drugsresistance to therapyresistant to therapyresponseretinoblastoma-1safety and feasibilityserious adverse experienceserious adverse reactionskeletal imagingsmall cell lung carcinomasmall cell undifferentiated carcinomatargeted agenttargeted imagingtheranosticstherapeutic efficacytherapeutic radionuclidetherapeutic resistancetherapy efficacytherapy resistanttooltranslationtreatment effecttreatment resistancetreatment strategytreatment with radiationtumortumor biomarkertumor cell metastasistumor heterogeneitytumor specific biomarkeruptakevalidations♂
Description preview
PROJECT ABSTRACT
Small cell lung cancer (SCLC) and neuroendocrine prostate cancer (NEPC) are aggressive, high-grade
neuroendocrine neoplasms (HG-NENs) that often metastasize and do not respond well to treatment. Lung
cancer is the leading cause of cancer mortality worldwide and SCLC represents ~15% of lung cancers. Prostate
cancer is the most…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click